Dyadic International (DYAI) investor relations material

Executive summary

• Achieved 182% year-over-year revenue growth to $1.11 million in Q1 2026, driven by new product launches, milestone payments, and expanded commercial partnerships in life sciences, food, and nutrition sectors.

• Transitioned to a commercially focused biotechnology business, leveraging proprietary C1 and Dapibus microbial production platforms for scalable, animal-free solutions.

• Broadened global reach through new distribution agreements and partnerships in Asia and Europe, including IBT Bioservices, FermBox Bio, and Intralink.

• Advanced biopharmaceutical programs with Gates Foundation and CEPI, generating non-dilutive funding and validating technology.

• Launched key products such as AlbuFree DX and DNase I, with profit-sharing and OEM agreements supporting commercialization.

Financial highlights

• Q1 2026 revenue was $1.11 million, up from $393,572 in Q1 2025, mainly from research, grant, and milestone revenues.

• Net loss for Q1 2026 was $1.95 million ($0.05/share), improved from $2.03 million ($0.07/share) a year ago.

• Cash, cash equivalents, restricted cash, and investment-grade securities totaled $6.6 million as of March 31, 2026.

• G&A expenses rose 10% year-over-year to $1,755,331, mainly due to legal, accounting, and business development costs.

• R&D expenses decreased 3.8% year-over-year to $476,069.

Outlook and guidance

• Expects continued growth in recurring product revenues across life sciences and food/nutrition, supported by recent launches and expanding customer engagement.

• Focused on building recurring revenue and maintaining disciplined cash management, with operating expenses expected to remain in line with 2025.

• Cash runway projected into Q2 2027, with liquidity sufficient for at least 12 months; evaluating strategic partnerships and capital markets for further balance sheet strength.

• Management anticipates continued losses and negative cash flows as commercialization efforts expand.

• Ongoing expansion of business development initiatives in Europe and Asia to support long-term growth.